Sorafenib potentiates irradiation effect in hepatocellular carcinoma in vitro and in vivo

Cancer Letters

Volumn 329, Issue 1, 2013, Pages 109-117

  Yu, Wen ^a,b   Gu, Ke ^a,b,c   Yu, Zhan ^a,b   Yuan, Dexiao ^b   He, Mingyuan ^b   Ma, Ningyi ^a,b   Lai, Songtao ^a,b   Zhao, Jiandong ^a,b   Ren, Zhigang ^a,b   Zhang, Xiaomeng ^a,b   Shao, Chunlin ^b   Jiang, Guo Liang ^a,b  

^a FUDAN UNIVERSITY SHANGHAI CANCER CENTER   (China)

^b FUDAN UNIVERSITY   (China)

^c SUZHOU MUNICIPAL HOSPITAL   (China)

Author keywords

Hepatocellular carcinoma; In vitro; Radiotherapy; Sorafenib; Xenograft model

Indexed keywords

IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; SORAFENIB; VASCULOTROPIN C;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER RADIOTHERAPY; CONTROLLED STUDY; DNA DAMAGE; DNA REPAIR; DOSE RESPONSE; DOSIMETRY; DOWN REGULATION; DRUG EFFECT; DRUG MECHANISM; DRUG MEGADOSE; DRUG POTENTIATION; DRUG TARGETING; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LIVER CELL CARCINOMA; MOUSE; NONHUMAN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; RADIOSENSITIVITY; SIGNAL TRANSDUCTION; THERAPY EFFECT;

ANIMALS; APOPTOSIS; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; COMBINED MODALITY THERAPY; DNA DAMAGE; DNA REPAIR; FEMALE; LIVER NEOPLASMS; MAP KINASE SIGNALING SYSTEM; MICE; MICE, INBRED BALB C; NF-KAPPA B; NIACINAMIDE; PHENYLUREA COMPOUNDS; PHOSPHORYLATION; RADIATION-SENSITIZING AGENTS; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84871715837     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2012.10.024     Document Type: Article

References (21)

1. Parkin D.M., Bray F., Ferlay J., Pisani P. Global cancer statistics, 2002. CA Cancer J. Clin. 2005, 55:74-108.
2. Hawkins M.A., Dawson L.A. Radiation therapy for hepatocellular carcinoma: from palliation to cure. Cancer 2006, 106:1653-1663.
3. Ren Z.G., Zhao J.D., Gu K., et al. Three-dimensional conformal radiation therapy and intensity-modulated radiation therapy combined with transcatheter arterial chemoembolization for locally advanced hepatocellular carcinoma: an irradiation dose escalation study. Int. J. Radiat. Oncol. Biol. Phys. 2011, 79:496-502.
4. Tang W.Y., Chau S.P., Tsang W.P., Kong S.K., Kwok T.T. The role of Raf-1 in radiation resistance of human hepatocellular carcinoma HepG2 cells. Oncol. Rep. 2004, 12:1349-1354.
5. Gorski D.H., Beckett M.A., Jaskowiak N.T., et al. Blockage of the vascular endothelial growth factor stress response increases the antitumor effects of ionizing radiation. Cancer Res. 1999, 59:3374-3378.
6. Liu Y., Poon R.T., Li Q., Kok T.W., Lau C., Fan S.T. Both antiangiogenesis- and angiogenesis-independent effects are responsible for hepatocellular carcinoma growth arrest by tyrosine kinase inhibitor PTK787/ZK222584. Cancer Res. 2005, 65:3691-3699.
7. Wilhelm S.M., Carter C., Tang L., et al. BAY43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res. 2004, 64:7099-7109.
8. Llovet J.M., Ricci S., Mazzaferro V., et al. Sorafenib in advanced hepatocellular carcinoma. N. Engl. J. Med. 2008, 359:378-390.
9. Ma X.J., Chen X.P. Relationship between the radiosensitivity of hepatic carcinoma cells and their survivin expression levels. Zhonghua Gan Zang Bing Za Zhi 2008, 6:207-209. (Chinese).
10. Zhang Z., Zhou X., Shen H., Wang D., Wang Y. Phosphorylated ERK is a potential predictor of sensitivity to sorafenib when treating hepatocellular carcinoma: evidence from an in vitro study. BMC Med. 2009, 7:41.
11. Doerr R., Zvibel I., Chiuten D., D'Olimpio J., Reid L.M. Clonal growth of tumors on tissue-specific biomatrices and correlation with organ site specificity of metastases. Cancer Res. 1989, 49:384-392.
12. Sridhar S.S., Hedley D., Siu L.L. Raf kinase as a target for anticancer therapeutics. Mol. Cancer Ther. 2005, 4:677-685.
13. Moynahan M.E., Chiu J.W., Koller B.H., Jasin M. Brca1 controls homology-directed DNA repair. Mol. Cell. 1999, 4:511-518.
14. Snouwaert J.N., Gowen L.C., Latour A.M., et al. BRCA1 deficient embryonic stem cells display a decreased homologous recombination frequency and an increased frequency of non-homologous recombination that is corrected by expression of a brca1 transgene. Oncogene 1999, 18:7900-7907.
15. Burma S., Chen B.P., Chen D.J. Role of non-homologous end joining (NHEJ) in maintaining genomic integrity. DNA Repair 2006, 5:1042-1048.
16. Barkett M., Gilmore T.D. Control of apoptosis by Rel/NF-kappaB transcription factors. Oncogene 1999, 18:6910-6924.
17. Plastaras J.P., Kim S.H., Liu Y.Y., et al. Cell cycle dependent and schedule-dependent antitumor effects of sorafenib combined with radiation. Cancer Res. 2007, 67:9443-9454.
18. Suen A.W., Galoforo S., Marples B., et al. Sorafenib and radiation: a promising combination in colorectal cancer. Int. J. Radiat. Oncol. Biol. Phys. 2010, 78:213-220.
19. Wachsberger P., Burd R., Dicker A.P. Tumor response to ionizing radiation combined with antiangiogenesis or vascular targeting agents: exploring mechanisms of interaction. Clin. Cancer Res. 2003, 9:1957-1971.
20. Herrera F.G., Lunt S.J., Fyles A., et al. Sorafenib (BAY43-9006) protects normal murine gut from radiation damage [abstract]. Int. J. Radiat. Oncol. Biol. Phys. 2007, 69(Suppl.3):S125.
21. Zhao J.D., Liu J., Ren Z.G., et al. Maintenance of sorafenib following combined therapy of three-dimensional conformal radiation therapy/intensity-modulated radiation therapy and transcatheter arterial chemoembolization in patients with locally advanced hepatocellular carcinoma: a phase I/II study. Radiat. Oncol. 2010, 5:12.